<DOC>
	<DOCNO>NCT02794571</DOCNO>
	<brief_summary>This first-in-human open-label , multicenter , dose-escalation study design evaluate safety , tolerability , PK MTIG7192A alone combination atezolizumab participant locally advance , recurrent , metastatic incurable tumor standard therapy exist , proven ineffective intolerable , consider inappropriate , clinical trial investigational agent recognize standard care .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Escalating Doses MTIG7192A Single Agent Combination With Atezolizumab Locally Advanced Metastatic Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults 18 year age old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Adequate hematologic end organ function Histologic documentation locally advance , recurrent , metastatic incurable malignancy progress least one available standard therapy ; standard therapy proven ineffective , intolerable , consider inappropriate ; clinical trial investigational agent recognize standard care Confirmed availability representative tumor specimens Measurable disease accord RECIST Version 1.1 Any anticancer therapy , whether investigational approve , include chemotherapy , hormonal therapy , radiotherapy , within 3 week prior initiation study treatment Malignancies disease study within 5 year prior Day 1 Cycle 1 Primary central nervous system ( CNS ) malignancy , untreated/active CNS metastases Leptomeningeal disease History idiopathic pulmonary fibrosis , pneumonitis , organize pneumonia , evidence active pneumonitis Screening chest compute tomograph ( CT ) scan History autoimmune disease Positive human immunodeficiency virus ( HIV ) test Active hepatitis B C , tuberculosis Severe infection within 4 week prior randomization Prior allogeneic bone marrow solid organ transplant Significant cardiovascular disease Known clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>